title: Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk.
abstract: BACKGROUND
  Cutaneous T-cell lymphoma occurring in the context of posttransplant immunosuppression is rare, with 27 cases documented to date.
  
  
  METHODS
  We report 2 new cases of posttransplant cutaneous T-cell lymphoma in patients treated at our institution. Both were male recipients of renal transplants who had undergone transplantation a mean of 5.3 years previously and were taking various multidrug immunosuppressive regimens, including cyclosporine, tacrolimus, mycophenolate mofetil, and prednisone.
  
  
  CONCLUSIONS
  These cases underscore the association of posttransplant cutaneous T-cell lymphoma with renal transplantation, cyclosporine and tacrolimus therapy, male sex, and later onset compared with B-cell posttransplant lymphoproliferative disease. Relative to the general population, the incidence of cutaneous T-cell lymphoma seems increased among transplant recipients receiving immunosuppressive medications.
authors.affiliation: Department of Dermatology, University of Pittsburgh School of Medicine, Presby South Tower, Ste 3880, 200 Lothrop St, Pittsburgh, PA 15213, USA.
authors.forename: Rebecca G
authors.initials: RG
authors.lastname: Pomerantz
authors.forename: Lauren S
authors.initials: LS
authors.lastname: Campbell
authors.forename: Drazen M
authors.initials: DM
authors.lastname: Jukic
authors.forename: Larisa J
authors.initials: LJ
authors.lastname: Geskin
mesh_terms: D000328:Adult; D000368:Aged; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000379:methods*; D016410:Lymphoma, T-Cell, Cutaneous / Q000139:chemically induced* / Q000209:etiology; D008297:Male; D012307:Risk Factors; D012737:Sex Factors; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000209:etiology; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus